{"organizations": [], "uuid": "373b48c01fef038b298098188ef2ff5a2dc8acaa", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources/r/?m=02&d=20180509&t=2&i=1260134394&w=1200&r=LYNXMPEE4819R", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/us-mylan-epipen-fda/fda-says-manufacturing-delays-are-constraining-epipen-supply-idUSKBN1IA1UW", "country": "US", "domain_rank": 408, "title": "FDA says manufacturing delays are constraining EpiPen supply", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-09T15:28:00.000+03:00", "replies_count": 0, "uuid": "373b48c01fef038b298098188ef2ff5a2dc8acaa"}, "author": "", "url": "https://www.reuters.com/article/us-mylan-epipen-fda/fda-says-manufacturing-delays-are-constraining-epipen-supply-idUSKBN1IA1UW", "ord_in_thread": 0, "title": "FDA says manufacturing delays are constraining EpiPen supply", "locations": [], "entities": {"persons": [{"name": "franklin paul", "sentiment": "none"}, {"name": "michael erman", "sentiment": "none"}], "locations": [{"name": "u.s.", "sentiment": "none"}, {"name": "new york", "sentiment": "none"}, {"name": "washington", "sentiment": "none"}], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "reuters staff", "sentiment": "none"}, {"name": "mylan", "sentiment": "none"}, {"name": "u.s. food and drug administration", "sentiment": "none"}, {"name": "mylan nv", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 9, 2018 / 12:36 PM / Updated 3 hours ago FDA says manufacturing delays are constraining EpiPen supply Reuters Staff 1 Min Read\nNEW YORK (Reuters) - The U.S. Food and Drug Administration added Mylan NV’s ( MYL.O ) EpiPen to its list of drugs in shortage on Wednesday, saying that manufacturing delays were creating intermittent supply constraints of the emergency allergy treatment.\nThe FDA said the status of Epipen, a lower dose version called EpiPen Jr, and Mylan’s own generic versions of those products were currently available, but that “supply levels may vary across wholesalers and pharmacies.” Reporting by Michael Erman, Editing by Franklin Paul", "external_links": [], "published": "2018-05-09T15:28:00.000+03:00", "crawled": "2018-05-09T15:42:30.000+03:00", "highlightTitle": ""}